Provided by Tiger Trade Technology Pte. Ltd.

KEYMED BIO-B

60.250
-0.300-0.50%
Volume:2.68M
Turnover:163.73M
Market Cap:18.01B
PE:-27.85
High:63.000
Open:61.200
Low:59.150
Close:60.550
52wk High:80.000
52wk Low:34.150
Shares:299.00M
HK Float Shares:299.00M
Volume Ratio:1.13
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-2.163
ROE:-19.91%
ROA:-10.37%
PB:5.73
PE(LYR):-27.85
PS:22.20

Loading ...

Lepu Biopharma Says AstraZeneca Begins Phase 3 Trial of CMG901 Cancer Therapy; Shares Jump 7%

MT Newswires Live
·
Mar 11

BRIEF-Keymed Biosciences Updates On Collaboration With Astrazeneca On Core Product CMG901 (AZD0901)

Reuters
·
Mar 10

KEYMED BIO-B (02162) Announces AstraZeneca Initiates Clinical Trial for CMG901 (AZD0901) with First Patient Dosed

Stock News
·
Mar 10

KeyMed Biosciences Inc - Update on Collaboration With AstraZeneca on Core Product Cmg901 (Azd0901)

THOMSON REUTERS
·
Mar 10

KeyMed Biosciences Inc - AstraZeneca Initiates Phase Iii Study of Azd0901 for Advanced Gastric Cancer

THOMSON REUTERS
·
Mar 10

Keymed Biosciences receives USD45 million CMG901 milestone payment from AstraZeneca

Reuters
·
Mar 10

Biopharma Stocks Rally as Sector Gains Strategic "Emerging Pillar" Status

Stock News
·
Mar 06

Keymed Biosciences Inc. (02162): February 2026 Monthly Securities Movement Update

Bulletin Express
·
Mar 02

Pinning Down Keymed Biosciences Inc.'s (HKG:2162) P/S Is Difficult Right Now

Simply Wall St.
·
Feb 03

Keymed Biosciences Inc. (02162) Announces January 2026 Monthly Return

Bulletin Express
·
Feb 02

Hong Kong Stocks Movement | KEYMED BIO-B (02162) Rises Nearly 3%, Self-Developed BCMA×CD3 Bispecific Antibody CM336 Granted FTD Designation by FDA

Stock News
·
Jan 27

HK Stock Movement | KEYMED BIO-B (02162) Opens Over 4% Higher as Sprifermin Injection Included in National Reimbursement Drug List

Stock News
·
Dec 08, 2025

Keymed Biosciences Inc. (02162) Reports Steady Share Capital for November 2025

Bulletin Express
·
Dec 01, 2025

HK Stock Movement | KEYMED BIO-B (02162) Rises Over 4% as Institutions Bullish on CM512's Global Value; Spesolimab Sales Expected to Accelerate Next Year

Stock News
·
Nov 25, 2025

China Post Securities: Rapid Clinical Progress in Autoimmune Bispecific Antibodies, Sustained Trading and R&D Momentum

Stock News
·
Nov 18, 2025

HK Stock Connect Shareholding Changes | November 12

Stock News
·
Nov 12, 2025

Why Is Keymed Biosciences (SEHK:2162) Drawing Big-Name Support After Stapokibart’s Approval in China?

Simply Wall St.
·
Nov 06, 2025

HK Stock Movement | KEYMED BIO-B (02162) Rises Over 3% Against Market Trend as CM512 Phase I Trial for Atopic Dermatitis Meets All Endpoints

Stock News
·
Nov 05, 2025

HK Stock Movement | KEYMED BIO-B (02162) Surges Over 7% as Goldman Sachs Highlights Stapokibart's Potential to Establish Valuation Foundation

Stock News
·
Nov 03, 2025

Southbound Capital Flow Statistics (T+2) | November 3

Stock News
·
Nov 03, 2025